plots and bias plots were analyzed for the rest of the thyroid assays as well as the fertility and oncology assays.
Fully Automated Enzyme Immunoassay System for the Determination of Activator-specific Histamine Release from Basophils in Whole Blood, Priscilla K Zia, Nasrin Namei, Ashok Patel, 1 Kris J. Kontis, 1* Narayan Nayak, 1 Roy Chen, 2 and Thomas M. Li 1 ( 1 Hycor Biomedical Inc., Garden Grove, CA 92841; 2 Becton Dickinson, San Jose, CA 95131; * author for correspondence: fax 714-895-6920, e-mail kjkontis@ix.netcom.com) Histamine release from washed leukocytes and/or whole blood has been extensively utilized for in vitro studies of allergy (1) (2) (3) (4) (5) . It has been shown that when the history and skin test of an individual are positive for a given activator, the probability is very high that the in vitro tests will also be positive for histamine release (6) . Throughout the past 10 years, numerous methods have been developed for the determination of histamine release. The commercially available RIA and enzyme immunoassay (EIA) kits for histamine release are not automated and require the investigator to provide the activators or compounds to be used in stimulating histamine release. This study de- The assay is performed on the HY⅐TEC TM System, a fully automated laboratory analyzer with existing methods for allergy and autoimmune diagnostics. All of the components, including the allergen extracts (activators), histamine-coated microtiter plates, buffers, and conjugate, are available from Hycor Biomedical Inc. The HY⅐TEC BHR TM is a competitive assay based on a mouse monoclonal anti-histamine antibody-alkaline phosphatase conjugate.
Sixteen histamine analogs and other amines including spermidine and spermine were tested for cross-reaction in the assay system. Each compound was assayed by the histamine EIA at three concentrations: 10, 20, and 1000 mg/L. The histamine EIA result for each concentration, expressed as milligrams per liter, was divided by the corresponding concentration. For example, a compound at a concentration of 1000 mg/L with a histamine EIA result of 0.02 mg/L would have the following crossreactivity:
All of the compounds had undetectable (Ͻ0.001%) or very low cross-reactivity (Ͻ0.2%).
The detection limit of this assay (mean of the zero calibrator plus two standard deviations, n ϭ 20) was 10 g/L.
The intraassay and interassay CVs were determined by assaying three buffer controls of low, medium, and high values of histamine in six replicates per assay with 11 assays. Histamine challenge and spontaneous and total release of whole blood samples were also determined in replicates. The intraassay and interassay CVs with buffer controls were determined to be 5.1-7.3% and 7.7-11.6%, respectively. The average intraassay variations for histamine challenge and spontaneous and total release of whole blood samples were 13.0%, 9.5%, and 9.7%, respectively.
Recovery of added histamine was studied in four freshly drawn whole blood samples, 1.0 mL each, with the addition of 20 L of each of five histamine stock solutions, 0 -8000 mg/L of histamine (blood samples were obtained from all subjects only after informed consent was documented on approved forms on file at Hycor Biomedical Inc., Garden Grove, CA). These samples were assayed with 50 L of activator diluent in place of activator predispensed in microtubes. Recoveries of histamine were 97.6 -132%.
Four whole blood samples with added histamine were serially diluted with sample and assayed by the HY⅐TEC System in the routine method but using 50 L of activator diluent instead of activator predispensed in microtubes.
The plot of the expected value at each dilution vs its corresponding measured value for all four samples with added histamine were demonstrated to be linear, with the slope, intercept, and correlation coefficient of 0.998, 1.78 g/L, and 0.998, respectively. The observed values were 91.9 -111% of those expected (mean, 102%).
Thirty-two samples with added histamine and 30 whole blood samples were assayed by the Immunotech Histamine RIA and the HY⅐TEC BHR EIA. The correlation between the two methods was determined for all 62 samples. The slope was 1.2, and the intercept was 3.5 g/L (r ϭ 0.97).
A preliminary clinical study was performed in six men and two women, of ages 28 -50. Care was taken to test the subjects only after confirming that no antihistamines, beta-2-agonists, cromolyn, or theophylline were being taken. Heparinized whole blood samples were challenged with dilutions of seven activator extracts (five foods and two grasses), using HY⅐TEC BHR. A cutoff of 15 g/L histamine observed at any dilution was used to define a positive response. Fig. 1 shows a representative plot of results from a blood sample from a test subject with a dramatic increase in histamine release at increased concentrations of June grass (G8). Dose-dependent release of histamine was also observed with increasing concentrations of anti-IgE. At higher concentrations of G8 or anti-IgE, histamine release diminishes, as expected for a typical IgE-dependent response. The response to cow milk extract (F2) was very weak. These results are in Fig. 1 . Histamine release from a whole blood sample stimulated with June grass pollen extract (G8), cow milk extract (F2), and anti-IgE.
Histamine in micrograms per liter is plotted against the log of the dilution factor for each activator and anti IgE. The highest concentration of anti-IgE used was 10 mg/L. agreement with specific serum IgE determinations and skin prick tests performed on the sample donor. Concordance tables were constructed to compare the HY⅐TEC BHR with skin prick tests and specific IgE tests for all of the activators used in the study. Similar comparisons were done using only the data from the two inhalant activators, Timothy grass and June grass pollen extracts. Table 1 shows the concordance with skin prick testing, specific IgE measurements, and the Biomerica RIA method. When only the results for the grass activators are considered, the concordances are Ͼ90%. This high degree of concordance with inhalant activators is in agreement with similar comparisons made by other investigators using different histamine assay methods.
The BHR method presented here is rapid, precise, specific, fully automated, and has potential uses in a number of clinical situations. We conclude that the many advantageous features of the HY⅐TEC BHR Assay will make it attractive to clinical investigators as a powerful adjunct for the diagnosis and treatment of allergy and hypersensitivity. DNA microarray technology is revolutionizing the analysis of genetic information by enabling the high-throughput analysis of gene mutations and gene expression. This has been made possible by the development of technologies that can synthesize thousands of oligonucleotide probes in situ (1), and high-speed robotic "printing" of cDNA probes (2) on a glass chip coupled with fluorescent labeling and detection of hybridized nucleic acids.
The technologies involved in such analyses are out of the reach of low-budget research and clinical laboratories. Here we demonstrate the use of chemiluminescent detection in a simple and inexpensive method of detecting plasmid DNA and oligonucleotide arrays on nylon membranes and glass slides.
A new method for rapid chemiluminescent detection of DNA arrays on nylon membranes and glass slides was developed using an ultrasensitive chemiluminescent reagent, Lumigen TM APS-5 (Fig. 1A) . The speed, sensitivity, and resolution of DNA spotted in low-and mediumdensity arrays was assessed with this reagent using several solid supports.
Lumigen APS-5 Chemiluminescent Substrate (Lumigen, Inc.) is supplied as an optimized formulation containing the substrate Lumigen APS-5 and lucigenin in pH 8.8 Tris buffer. DNA was spotted manually with finetipped pipet prepared by drawing out a Pasteur pipet over a flame. Higher density arrays were applied under a dissecting microscope. Nylon membranes from several commercial suppliers were evaluated, and polylysinecoated glass slides were from Sigma Chemical Co. The spotting was done in rows or in 1 ϫ 1 or 2 ϫ 2 cm grids with a 1-mm spot separation to provide arrays of 100 and 400 spots, respectively. Spot size varied with the pipet tip and was not controlled. Spot size was also influenced by the wicking property of the membranes used (see below). The nominal amount of DNA delivered per spot was calculated from the volume and concentration of stock DNA divided by the number of spots applied. The nominal amount of labeled plasmid DNA per spot was 0.5 pg or 10 pg for direct detection, and 1, 10, or 100 pg or 1 ng for detection by hybridization. In the cystic fibrosis (CF) assay, the amounts of oligonucleotides delivered per spot varied between experiments from 1 to 40 ng. The spotted plasmid DNA and oligonucleotides on the membrane and glass slides were UV cross-linked for 30 s at 120 mJ/cm 2 with a Hoefer UV cross-linker. Digoxigenin (dig)-labeled pBR328 plasmid DNA was spotted and detected without hybridization, using anti-digalkaline phosphatase (AP) conjugate and Lumigen APS-5 (Lumigen). In a hybridization format, unlabeled pBR328 plasmid DNA was spotted, hybridized with a dig-labeled pBR328 probe according to standard protocols, and then 
